ArticleLeukemia2021

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.

Rémi Letestu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.